RWD & AI: Boost Performance & Innovation
- Parkinson's disease,a complex neurodegenerative disorder,affects nearly 1 million people in the U.S., with about 90,000 new diagnoses each year.
- Dr.Heather Moss, medical advisor at Verana Health and professor at Stanford University, said traditional clinical trials face hurdles such as high costs and limited generalizability.
- However, leveraging real-world data and artificial intelligence offers a transformative approach to Parkinson's research, possibly leading to earlier diagnoses and personalized treatments.
Real-world data (RWD) and artificial intelligence (AI) are reshaping Parkinson’s research, promising earlier diagnoses and personalized treatments for the nearly 1 million Americans affected.This article explores how RWD, sourced from electronic health records and specialty clinical registries, offers a comprehensive patient journey view, unveiling patterns often unseen in traditional trials. AI algorithms then unlock hidden insights within this data, driving innovation in treatment and care.Collaboration is key to harnessing the full potential of this powerful combination, as we learn about Dr. Heather Moss’s work. at News Directory 3, we bring you the latest breakthroughs in technology and healthcare. Discover what’s next in the fight against Parkinson’s.
AI and Real-World Data Transforming Parkinson’s Research
Updated June 26,2025
Parkinson’s disease,a complex neurodegenerative disorder,affects nearly 1 million people in the U.S., with about 90,000 new diagnoses each year. The disease presents diverse motor and non-motor symptoms, making effective treatments difficult to develop.
Dr.Heather Moss, medical advisor at Verana Health and professor at Stanford University, said traditional clinical trials face hurdles such as high costs and limited generalizability. Many exclude older adults or those with coexisting conditions, failing to represent the broader Parkinson’s community.
However, leveraging real-world data and artificial intelligence offers a transformative approach to Parkinson’s research, possibly leading to earlier diagnoses and personalized treatments. Real-world data, gathered from electronic health records and specialty clinical registries, provides a comprehensive view of a patient’s health journey, illuminating patterns frequently enough missed in controlled trials.
Analyzing real